National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics
Contract Funds 3D Breast Cancer, 3D Brain Cancer Micro-Tumor Development
GREENVILLE, SC | September 18, 2014 – KIYATEC announced today that it has been awarded a $1.975 million, Small Business Innovation Research (SBIR) Phase II Contract from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). Over the course of the two year award, KIYATEC will expand its 3D breast cancer model to address two issues at the forefront of cancer therapy strategies: 1) cancer’s interaction with the patient’s immune system (immuno-oncology) and 2) cancer’s interaction with the patient’s blood supply (angiogenesis). The award will also allow KIYATEC to broaden its technology platform beyond its current use in primary ovarian cancer and breast cancer testing and into glioblastoma multiforme (GBM), a type of brain cancer with a five year survival rate that is less than 10 percent. The funded contract has the potential to radically change the future of cancer patient care.